These findings provide a new perspective on the underlying molecular mechanism of PC, suggesting that LAMC2 and RUNX2 may be valuable biomarkers and therapeutic targets for PC patients and may also offer powerful evidence and clues for the future genomic individualized treatment of PC. This evidence concerns the gene LAMC2 and pachyonychia congenita.